New drug aims to shield cancer patients from chemo side effect
NCT ID NCT07205536
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a drug called mecapegfilgrastim can safely prevent moderate-to-severe myelosuppression (low blood cell counts) caused by chemotherapy and radiation for lung or esophageal cancer. About 30 adults aged 18-75 will receive the drug alongside their standard cancer treatment. Researchers will monitor blood counts and other side effects to see if the drug helps reduce complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMORADIOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Nantong University
RECRUITINGNantong, Jiangsu, 226001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immunotherapy cocktail shrink inoperable lung tumors?
- Could everyday heart drugs shield cancer patients from Radiation's cardiac toll?
- Brain tumor patients with severe symptoms may get a new treatment option
- New drug combo aims to fight lung cancer after chemoradiation
- New immunotherapy combo aims to improve lung cancer outcomes
- Can what you eat during cancer treatment change your survival?